Alpa Laboratories Share Price Today (ALPA)
TODAY IN ONE LINE
ALPA fell 2.4% on light volume, lagging Nifty's -0.9% move.
With a market cap of ₹142.19 Cr., it trades at a P/E of 12.09. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Alpa Laboratories flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Reasonable ValuationTrading at a moderate P/E of 12.1x
- ●High Promoter HoldingPromoters hold 57.2% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Sales ContractionQuarterly sales dropped 21.3% YoY
- ●Poor Capital ReturnsLow ROE of 8.4%
- ●Rising Receivables vs SalesReceivables grew 14.2% outpacing sales growth of 3.4%
Latest Alpa Laboratories News
What changed recently?
Recent events, corporate actions, and announcements.
Alpa Laboratories Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Alpa Laboratories Limited, framed against the sector median so the premium or discount is obvious at a glance.
Alpa Laboratories Limited trades at a P/E of 12.09× and P/B of 0.77×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Alpa Laboratories Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Alpa Laboratories Limited — derived from the live tape, not yesterday's close.
Alpa Laboratories Limited last traded at ₹66.02 with an intraday range of ₹66.02–₹69.64 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹66.02| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 75.67 | +9.65 | +14.62% |
| R3 | 72.05 | +6.03 | +9.14% |
| R2 | 70.85 | +4.83 | +7.31% |
| R1 | 68.43 | +2.41 | +3.66% |
| PIVOT | 67.23 | 1.21 | 1.83% |
| CURRENT | 66.02 | — | — |
| S1 | 64.81 | -1.21 | -1.83% |
| S2 | 63.61 | -2.41 | -3.66% |
| S3 | 61.19 | -4.83 | -7.31% |
| S4 | 57.57 | -8.45 | -12.79% |
ALPA is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹67.64–₹69.64
Trading Below opening range, showing Bearishness
Alpa Laboratories Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Alpa Laboratories Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Alpa Laboratories Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹142.19 Cr. and reported EPS of ₹7.14.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 112 | 106 ▼ 5.9% |
| Sales Growth YoY %Derived | 3.41% | -5.91% |
| Other Income | 23 | 16 ▼ 32.5% |
| Total Income | 136 | 122 ▼ 10.5% |
| 70 | 66 ▼ 5.5% | |
| Gross ProfitDerived | 42 | 39 ▼ 6.6% |
| Gross Margin %Derived | 37.57% | 37.28% |
| 38 | 36 ▼ 3.6% | |
| EBITDA (Operating Profit)Derived | 5 | 3 ▼ 30.8% |
| OPM %Derived | 4.23% | 3.11% |
| 2 | 1 ▼ 39.8% | |
| Profit Before Tax (PBT) | 26 | 16 ▼ 38.4% |
| 6 | 2 ▼ 72.6% | |
| Effective Tax %Derived | 24.01% | 10.67% |
| Total Profit for Period | 20 | 14 ▼ 27.6% |
| Net Profit (Owner's PAT)Derived | 20 | 14 ▼ 27.6% |
| Net Profit Margin %Derived | 17.34% | 13.35% |
| PAT Growth YoY %Derived | 16.25% | -27.57% |
| Earnings Per Share (EPS ₹) | 9.27 | 6.71 ▼ 27.6% |
| Diluted Shares Outstanding (Cr) | 2 | 2 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | 0 | — ▼ 100.0% |
| Total Expenses (incl. D&A & Interest) | 110 | 106 ▼ 4.0% |
| Material Cost % of RevenueDerived | 62.89% | 59.78% |
| Employee Cost % of RevenueDerived | 12.79% | 14.94% |
| Other Cost % of RevenueDerived | 20.56% | 19.24% |
| Interest Coverage (x)Derived | 11.01x | 4.65x |
| Period | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 86 | 98 ▲ 13.5% | 112 ▲ 15.1% | 92 ▼ 17.7% | 109 ▲ 17.6% | 112 ▲ 3.4% | 106 ▼ 5.9% | |
| Sales Growth YoY %Derived | — | 13.48% | 15.08% | -17.66% | 17.64% | 3.41% | -5.91% | |
| Other Income | 3 | 4 ▲ 50.9% | 11 ▲ 145.1% | 10 ▼ 7.8% | 15 ▲ 49.9% | 23 ▲ 56.8% | 16 ▼ 32.5% | |
| Total Income | 89 | 102 ▲ 14.7% | 123 ▲ 20.7% | 102 ▼ 16.8% | 124 ▲ 20.8% | 136 ▲ 9.8% | 122 ▼ 10.5% | |
51 | 59 ▲ 16.6% | 70 ▲ 17.3% | 57 ▼ 18.1% | 68 ▲ 19.0% | 70 ▲ 3.2% | 66 ▼ 5.5% | ||
| Gross ProfitDerived | 35 | 38 ▲ 8.9% | 42 ▲ 11.6% | 35 ▼ 17.0% | 41 ▲ 15.4% | 42 ▲ 3.8% | 39 ▼ 6.6% | |
| Gross Margin %Derived | 40.68% | 39.04% | 37.85% | 38.16% | 37.43% | 37.57% | 37.28% | |
32 | 30 ▼ 3.9% | 32 ▲ 4.6% | 28 ▼ 12.8% | 33 ▲ 17.6% | 38 ▲ 15.0% | 36 ▼ 3.6% | ||
| EBITDA (Operating Profit)Derived | 3 | 8 ▲ 129.2% | 11 ▲ 38.9% | 8 ▼ 29.3% | 8 ▲ 7.3% | 5 ▼ 41.4% | 3 ▼ 30.8% | |
| OPM %Derived | 3.90% | 7.88% | 9.52% | 8.17% | 7.45% | 4.23% | 3.11% | |
3 | 1 ▼ 61.1% | 2 ▲ 45.4% | 2 ▼ 18.5% | 2 ▲ 49.4% | 2 ▲ 5.2% | 1 ▼ 39.8% | ||
| Profit Before Tax (PBT) | 3 | 11 ▲ 270.8% | 20 ▲ 81.4% | 16 ▼ 18.5% | 21 ▲ 29.7% | 26 ▲ 24.1% | 16 ▼ 38.4% | |
1 | 4 ▲ 235.6% | 5 ▲ 54.6% | 3 ▼ 39.5% | 4 ▲ 18.1% | 6 ▲ 57.8% | 2 ▼ 72.6% | ||
| Effective Tax %Derived | 36.25% | 32.81% | 27.96% | 20.75% | 18.88% | 24.01% | 10.67% | |
| Total Profit for Period | 2 | 7 ▲ 290.8% | 14 ▲ 94.5% | 13 ▼ 10.4% | 17 ▲ 32.8% | 20 ▲ 16.3% | 14 ▼ 27.6% | |
| Net Profit (Owner's PAT)Derived | 2 | 7 ▲ 290.8% | 14 ▲ 94.5% | 13 ▼ 10.4% | 17 ▲ 32.8% | 20 ▲ 16.3% | 14 ▼ 27.6% | |
| Net Profit Margin %Derived | 2.16% | 7.43% | 12.55% | 13.67% | 15.43% | 17.34% | 13.35% | |
| PAT Growth YoY %Derived | — | 290.83% | 94.54% | -10.36% | 32.81% | 16.25% | -27.57% | |
| Earnings Per Share (EPS ₹) | 0.88 | 3.44 ▲ 290.9% | 6.70 ▲ 94.8% | 6.00 ▼ 10.4% | 7.97 ▲ 32.8% | 9.27 ▲ 16.3% | 6.71 ▼ 27.6% | |
| Diluted Shares Outstanding (Cr) | 2 | 2 ▲ 0.0% | 2 ▲ 0.0% | 2 ▲ 0.0% | 2 ▲ 0.0% | 2 ▲ 0.0% | 2 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | 0 | 0 ▼ 12.9% | -0 ▼ 404.6% | -0 ▼ 217.4% | 0 ▲ 138.9% | 0 ▲ 83.3% | — ▼ 100.0% | |
| Total Expenses (incl. D&A & Interest) | 86 | 91 ▲ 6.0% | 103 ▲ 13.5% | 86 ▼ 16.5% | 103 ▲ 19.1% | 110 ▲ 7.0% | 106 ▼ 4.0% | |
| Material Cost % of RevenueDerived | 57.56% | 55.59% | 56.49% | 59.14% | 57.83% | 62.89% | 59.78% | |
| Employee Cost % of RevenueDerived | 13.75% | 12.04% | 10.63% | 13.17% | 12.22% | 12.79% | 14.94% | |
| Other Cost % of RevenueDerived | 23.03% | 19.11% | 17.70% | 16.82% | 17.76% | 20.56% | 19.24% | |
| Interest Coverage (x)Derived | 0.98x | 82.97x | 37.17x | 27.89x | 17.13x | 11.01x | 4.65x |
Alpa Laboratories segment analysis : revenue and profit mix.
Disclosed business segments at Alpa Laboratories with their share of revenue and profit, switchable between consolidated and standalone reporting.
Alpa Laboratories discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Alpa Laboratories Limited.
Our AI distills the core fundamental drivers supporting Alpa Laboratories Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Alpa Laboratories Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Debt-free balance sheet with negligible D/E 0.0001x ensures robust financial stability.
Promoter holding stable at 57.19% signals strong management commitment and alignment.
Low P/E 9.48x trades 68% discount to peer median, indicating significant undervaluation.
Operating cash flow positive ₹18.39 Cr demonstrates improving liquidity generation.
5-year revenue CAGR 7.59% reflects steady long-term growth trajectory despite contraction.
Key Risks.
TTM revenue declined 21.4% YoY, signaling acute near-term earnings pressure and demand uncertainty.
Operating margin 1.13% critically thin versus peer averages, limiting pricing power severely.
Negative EBIT in multiple quarters (Q3 FY25. -₹29.13 Cr) signals operational volatility.
ROE 8.39% and ROCE 9.42% lag peer medians of 14.7% and 17.4% respectively.
High beta 1.15 amplifies stock volatility 15% above market, increasing downside risk.
Flip Conditions.
Valuation risk. a P/E above 16 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Alpa Laboratories Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Alpa Laboratories Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Alpa Laboratories Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Alpa Laboratories Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Alpa Laboratories Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Alpa Laboratories Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Alpa Laboratories Limited stood at 74.8% of traded volume, against a 20-day average of 65.9%.
Alpa Laboratories announcements: results, concalls, ratings, M&A.
Filings Alpa Laboratories sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Alpa Laboratories files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 26 documents below.
Cessation
Alpa Laboratories Limited has informed the Exchange regarding Cessation of Ms Yashoda Patidar as Company Secretary & Compliance Officer of the…
Trading Window
Alpa Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading)…
Clarification - Financial Results
The Exchange has sought clarification from Alpa Laboratories Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI…
Disclosure under SEBI Takeover Regulations
Alpa Laboratories Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India…
Appointment
Alpa Laboratories Limited has informed the Exchange regarding Appointment of Ms.Yashoda Patidar as Company Secretary & Compliance Officer of the…
Alpa Laboratories dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Alpa Laboratories has declared, sequenced by announce and record date.
Alpa Laboratories corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
Alpa Laboratories insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Alpa Laboratories as reported to SEBI — buying and selling signals from the people who know the business best.
Alpa Laboratories insider activity below tracks 7 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| VINIT SHAH | Insider | 07 Mar 2026 | buy | +21.9 K | — | — |
| BAKULESH CHANDULAL SHAH HUF | Insider | 07 Mar 2026 | buy | +21.9 K | — | — |
| VINIT SHAH | Insider | 07 Mar 2026 | buy | +21.9 K | — | — |
| BAKULESH CHANDULAL SHAH HUF | Insider | 07 Mar 2026 | buy | +21.9 K | — | — |
| Paresh Chawla | Insider | 17 Jun 2025 | buy | +35.22 L | — | — |
| Mahendra Singh Chawla | Insider | 17 Jun 2025 | sell | −29.06 L | — | — |
| Asha Chawla | Insider | 17 Jun 2025 | sell | −6.16 L | — | — |
About Alpa Laboratories Limited: business, sector, key facts.
What Alpa Laboratories Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Alpa Laboratories Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: ALPA, BSE: 532878.
ALPA Laboratories Limited is an Indian pharmaceutical company specializing in the manufacturing and sale of finished dosage forms of pharmaceutical products. Their product portfolio is diverse, encompassing a wide range of therapeutic categories and dosage forms to serve both human and veterinary healthcare needs.
The company's product offerings include ethical, generic, and over-the-counter (OTC) medications. These are available in various forms such as injections, tablets, capsules, topical preparations (creams, gels, ointments), and ophthalmic and otic (eye and ear) drops. The therapeutic categories covered are extensive and include anti-infectives (antibacterial, antibiotics, antifungals, antiprotozoals, and antivirals), analgesics, anti-inflammatory drugs, cough and cold medications, cardiovascular drugs, anti-diabetics, nutritional supplements, psychotropic drugs, and skincare preparations including ear and eye care products.
ALPA's distribution network is robust, utilizing a multi-channel approach to reach its customers. This includes collaborations with distributors, retail chemists, retail pharmacy stores, and hospitals within India. Furthermore, the company actively engages in international trade, exporting its products to various regions including South and Central America, Africa, Asia, Russia, Ukraine, and Kazakhstan, demonstrating a significant global reach.
Established in 1967 and headquartered in Indore, India, ALPA Laboratories Limited has a long history in the pharmaceutical industry. Its comprehensive product range, established distribution network, and international presence solidify its position as a significant player in the Indian and global pharmaceutical markets.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Alpa Laboratories Limited (ALPA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Alpa Laboratories Limited (ALPA)?
The current share price of Alpa Laboratories Limited (ALPA) is ₹66.02. Today, the stock has declined by ₹1.62 (2.40%), trading in a range of ₹66.02 to ₹69.64. The stock opened at ₹68.25 with a trading volume of 6,950 shares.
02Is Alpa Laboratories Limited stock a good investment for long-term?
Alpa Laboratories Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹142.19 crores, P/E ratio of 12.09, ROE of 8.39%, and ROCE of 9.42%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Alpa Laboratories Limited stock?
The 52-week high price of Alpa Laboratories Limited (ALPA) is ₹105.51, while the 52-week low is ₹46.1. Currently trading at ₹66.02, the stock is 33.5% away from its 52-week low and 37.4% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Alpa Laboratories Limited stock at the current price?
Whether to buy Alpa Laboratories Limited stock at ₹66.02 depends on multiple factors. The stock is currently trading with a P/E ratio of 12.09 and P/B ratio of 0.77. Today's performance shows a loss of 2.40%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Alpa Laboratories Limited and when is the next dividend?
Alpa Laboratories Limited offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹66.02, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Alpa Laboratories Limited?
Alpa Laboratories Limited's key financial metrics include: P/E Ratio: 12.09, P/B Ratio: 0.77, ROE: 8.39%, ROCE: 9.42%, Dividend Yield: 0.00%, EPS: ₹7.14, Book Value: ₹32.34, and Debt-to-Equity: 0.01. The company's market cap stands at ₹142.19 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Alpa Laboratories Limited stock performing today in the market?
Alpa Laboratories Limited stock opened at ₹68.25 and is currently trading at ₹66.02, showing a decline of ₹1.62 (2.40%). The intraday high is ₹69.64 and low is ₹66.02. The trading volume stands at 6,950 shares, indicating moderate market participation today.
08What is the P/E ratio of Alpa Laboratories Limited and what does it indicate?
Alpa Laboratories Limited has a Price-to-Earnings (P/E) ratio of 12.09, which means investors are willing to pay ₹12.09 for every ₹1 of earnings. With an EPS of ₹7.14, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Alpa Laboratories Limited (ALPA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.